Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06222164 · ClinicalTrials.gov registry record
The Use of Residual De-identified Specimens and/or Samples From Patients for Clinical Research
A clinical trial of Hematologic Diseases, sponsored by Invivoscribe.
- Recruiting
- Registry status
- 2,000
- Enrollment target
- 1
- Study location
NCT06222164 is a study of Hematologic Diseases that is actively recruiting participants, run by Invivoscribe. The registered enrollment target is 2,000 participants, roughly in line with the 2,120-participant average among 17 other Hematologic Diseases trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT06222164, a study of Hematologic Diseases, is actively recruiting participants, sponsored by Invivoscribe.
- RECRUITING
- Registry status
- 2,000 participants
- Enrollment target
- 1
- Study location
Study Summary
Acquire residual human specimens and/or samples from patient samples which were sent for testing at LabPMM, LLC for Clinical Research
Conditions Studied
Study Locations (1)
California
- LabPMM - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2024-03-30 |
| Est. Completion | 2027-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06222164
The ClinicalTrials.gov registry entry for NCT06222164 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 2,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 2,120-participant average among 17 other Hematologic Diseases trials with a reported enrollment target. The listed sponsor is Invivoscribe, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hematologic Diseases appearing as the primary indexed condition, and to 0 interventions.
NCT06222164 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06222164 about?
NCT06222164 is a clinical study titled "The Use of Residual De-identified Specimens and/or Samples From Patients for Clinical Research". Acquire residual human specimens and/or samples from patient samples which were sent for testing at LabPMM, LLC for Clinical Research
What is the current status of trial NCT06222164?
This trial is currently recruiting. The enrollment target is 2,000 participants. The study started on 2024-03-30. Estimated completion is 2027-06-30.
What conditions does trial NCT06222164 study?
This clinical trial studies the following conditions: Hematologic Diseases.
Who is sponsoring clinical trial NCT06222164?
This trial is sponsored by Invivoscribe, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06222164 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematologic Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Adults With T-allo10 Cells Addback
RECRUITING · Phase 1
-
Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Young Adults
RECRUITING · NA
-
HEME Home Transfusion Program
RECRUITING · NA
-
A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
RECRUITING · Phase 1
-
Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
RECRUITING · Phase 3
-
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.